Collaboration to expand HCS technology throughout China underway
SHANGHAI, China and PITTSBURGH, Sept. 2 /PRNewswire/ -- The National
Center for Drug Screening (NCDS) located in Shanghai, China and Cellomics,
Inc. of Pittsburgh, Pennsylvania, U.S.A. today announced a joint collaboration
aimed at expanding the application of High Content Screening (HCS) in China.
Affiliated with the Shanghai Institute of Materia Mecica, Chinese Academy of
Sciences, the Center is a key national technology innovation base in drug
discovery and development.
(Logo: http://www.newscom.com/cgi-bin/prnh/20010611/PHM032LOGO )
Cellomics, Inc., a privately held company, is recognized as the creator of
and market leader in HCS, providing a unique cell-based platform to its global
clients in pharmaceutical, biotechnology and academic institutions.
"We are very pleased to work with Cellomics as a strategic partner in the
establishment of an HCS program at the Center," stated Dr. Ming-Wei Wang,
Director of the NCDS. "By including the ArrayScan(R) HCS Reader with all of
the Cellomics' software, reagents and expertise in the implementation of HCS,
we are able to quickly execute our strategic plan for including high content
cell-based assays in our drug discovery and development efforts," continued
Dr. Wang.
"Our collaboration with Dr. Wang and the NCDS is critically important for
Cellomics," replied Daniel J. Calvo, President and CEO of Cellomics. "Through
this joint effort with China's leading drug discovery facility, we can expand
our global leadership position in HCS into China and the surrounding region.
We look forward to assisting this world-class laboratory in incorporating our
technology into their research programs," continued Calvo.
About NCDS
The National Center for Drug Screening was jointly set up by the Ministry
of Science and Technology, the Chinese Academy of Sciences and the Shanghai
Municipality Government. It offers a wide-range of drug screening services and
technical consultations to universities, research institutions and commercial
entities across China. Using its advanced technology platforms and high
quality services, and through external collaborations with biopharmaceutical
research and development institutions, the NCDS is playing an indispensable
role in the adequate utilization of compound resources nationwide and
promotion of innovative drug development. Focusing on major diseases that
affect the Chinese population (such as cancer, central nervous system
diseases, metabolic disorders and infectious diseases, etc.), the NCDS is
actively developing internationally advanced drug screening assays, performing
large-scale compound library screening and conducting downstream studies. The
establishment of the NCDS is an important milestone in modernizing China's
drug research and innovation system. For more information, please
visit http://www.screen.org.cn .
About Cellomics
Cellomics, Inc. is automating drug discovery through a unique, cell-based
assay platform that addresses the needs of Drug Discovery and Systems Biology
groups by offering complete systems for High Content Screening. The platform
includes HCS instrumentation (both fixed end-point and kinetic systems),
informatics, cellular image analysis software (BioApplications), fluorescent
reagents, kits, cell lines, and multiparametric assays. When applied to early
drug discovery, this platform is proving to reduce the 'idea-to-discovery'
cycle time in drug discovery, while increasing the probability of the
therapeutic success of leads as well as enhancing throughput in systems
biology and basic research. Cellomics' proprietary platforms, including the
ArrayScan and KineticScan(R) HCS Readers, along with BioApplications software
and High Content Informatics (HCi(TM)) suite, are in use at multiple sites
within all of the top fifteen pharmaceutical companies, as well as leading
pharmaceutical and biotechnology companies and academic centers globally. For
more information about Cellomics, visit our website
at http://www.cellomics.com .
For further information, contact:
Judy P. Masucci, Ph.D.
Director of Marketing
Cellomics, Inc.
100 Technology Drive
Pittsburgh, PA 15219
412-770-2200 x 2353
412-770-2450 (fax)
pr@cellomics.com
http://www.cellomics.com
Xin Xie, Ph.D.
Head, Department of Assay Development II
The National Center for Drug Screening
189 Guo Shou Jing Road
Shanghai 201203, P.R. China
21-50801313 x 186
21-50800721 (fax)
xxie@mail.shcnc.ac.cn
http://www.screen.org.cn
SOURCE Cellomics, Inc.; National Center for Drug Screening
 back to top
Related links:
http://www.cellomics.com
http://www.screen.org.cn
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20010611/PHM032LOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Judy P. Masucci, Ph.D., Director of Marketing
of Cellomics, Inc., +1-412-770-2200 ext. 2353, or fax,
+1-412-770-2450, or pr@cellomics.com, or Xin Xie, Ph.D., Head,
Department of Assay Development II of The National Center for
Drug Screening, 21-50801313 ext. 186, or fax, 21-50800721 or
xxie@mail.shcnc.ac.cn
|
